Oppenheimer analyst Michael Wiederhorn raised the firm’s price target on HCA Healthcare to $310 from $270 and keeps an Outperform rating on the shares. The firm notes HCA produced very strong Q1 and conservatively increased guidance by the beat, as the company continues to stay ahead of the pack while broader trends normalize.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on HCA:
